Preclinical immunogenicity and safety of the cGMP-grade placental malaria vaccine PRIMVACResearch in context
Background: VAR2CSA is the lead antigen for developing a vaccine that would protect pregnant women against placental malaria. A multi-system feasibility study has identified E. coli as a suitable bacterial expression platform allowing the production of recombinant VAR2CSA-DBL1x-2x (PRIMVAC) to envis...
Main Authors: | Arnaud Chêne, Stéphane Gangnard, Anna Guadall, Hervé Ginisty, Odile Leroy, Nicolas Havelange, Nicola K. Viebig, Benoît Gamain |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-04-01
|
Series: | EBioMedicine |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396419301501 |
Similar Items
-
Progress and Insights Toward an Effective Placental Malaria Vaccine
by: Benoît Gamain, et al.
Published: (2021-02-01) -
Characterization of novel rhodopsins with light-regulated cGMP production or cGMP degradation
by: Tian, Yuehui
Published: (2019) -
Studies on Characterization and Tissue Distribution of cGMP-binding cGMP-specific Phosphodiesterase
by: Kotera, Jun
Published: (2014) -
VAR2CSA-Mediated Host Defense Evasion of Plasmodium falciparum Infected Erythrocytes in Placental Malaria
by: Alice Tomlinson, et al.
Published: (2021-02-01) -
The Viewpoint of cGMP on Software Specification
by: YU YUAN CHANG, et al.
Published: (2005)